{"groups":[{"description":"Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma","id":"FG000","title":"Dasatinib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Three (3) participants withdrew from the study before treatment initiation; therefore 43 participants were eligible for evaluation","recruitmentDetails":"Between September 2007 to August 2009, 46 participants were recruited."}